LENZ Therapeutics, Inc.LENZNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank74
5Y CAGR+12.5%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+12.5%/yr
Long-term compound
Percentile
P74
Within normal range
vs 5Y Ago
1.8x
Solid growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 44.27% |
| Q3 2025 | 114.68% |
| Q2 2025 | 15.14% |
| Q1 2025 | 18.77% |
| Q4 2024 | 44.09% |
| Q3 2024 | -12.33% |
| Q2 2024 | 33.44% |
| Q1 2024 | 1.80% |
| Q4 2023 | 90.60% |
| Q3 2023 | 23.32% |
| Q2 2023 | 1.27% |
| Q1 2023 | 53.04% |
| Q4 2022 | -80.93% |
| Q3 2022 | 13.22% |
| Q2 2022 | 19.16% |
| Q1 2022 | -24.76% |
| Q4 2021 | 44.23% |
| Q3 2021 | 12.53% |
| Q2 2021 | 22.17% |
| Q1 2021 | 115.29% |
| Q4 2020 | 24.62% |
| Q3 2020 | 67.51% |
| Q2 2020 | 617.36% |
| Q1 2020 | 0.00% |